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Abstract
We would like to comment on the article entitled “Prognostic and diagnostic significance of copeptin in acute
exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from ACE 2 study” by Jacob A.
Winther and colleagues, in the light of the results of a multicentric study published in 2014 by Vetrone F. et al., in
which 336 patients with dyspnea were enrolled in the Emergency Departments of three University Hospitals in Italy.
These two studies confirm the prognostic role of copeptin in patients with dyspnea due to heart failure but, while
Winther et al. performed the copeptin measurements only at admission, Vetrone et al. evaluated the time-course of
copeptin plasma concentration from the admission to the hospital discharge. The results showed a better performance of
copeptin measured at discharge as prognostic biomarker compared to copeptin at hospital admission; similarly, a lower
reduction or an increase in copeptin concentration from admission to discharge was a strong prognostic predictor of
unfavorable outcome. In our opinion this is a very important result, opening new perspectives for the use of copeptin as
prognostic marker in HF patients.
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Dear Editor,
We read with interest the article entitled: “Prognostic
and diagnostic significance of copeptin in acute exacerba-
tion of chronic obstructive pulmonary disease and acute
heart failure: data from ACE 2 study” by Jacob A. Winther
and colleagues. The Authors evaluated the clinical useful-
ness of copeptin as a diagnostic tool and prognostic
marker, in comparison to NT-proBNP, in a population of
314 patients admitted because of acute dyspnea at the
Akersus University Hospital, in Norway [1].
Beside confirming that NT-proBNP better performs than
copeptin in differentiating patients with heart failure (HF)
related dyspnea from those complaining non-HF related
dyspnea, the Authors outlined how promising copeptin is
as prognostic biomarker. In fact, the major finding was that
the two biomarkers show similar accuracy in predicting 2-
years mortality in the group of HF patients. On the con-
trary, copeptin but not NT-proBNP, predicted mortality in
acute exacerbation of chronic obstructive pulmonary dis-
ease (AECOPD). These results raised several issues which
need to be further discussed at the light of the current lit-
erature dealing with this topic. Copeptin had already been
evaluated as short and long-term prognostic marker in
AECOPD, with conflicting results. Stolz et al. have re-
ported that copeptin levels at admission are correlated with
* Correspondence: luigi.castello@med.uniupo.it
Translational Medicine Department, Università del Piemonte Orientale, Via
Solaroli, 17, 28100 Novara, Italy
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Castello and Bellan Respiratory Research  (2018) 19:35 
https://doi.org/10.1186/s12931-018-0738-7
the length of the hospital stay; moreover copeptin was pre-
dictive for long-term clinical failure [2]. This finding is also
supported by the results of Boeck et al., who proposed a
simple score, inclusive of copeptin, which was predictive of
2-years mortality [3]. On the contrary, Dres et al. failed to
disclose an association between copeptin plasma concen-
tration and a short-term composite outcome (ER visit,
death or transfer to the Intensive Care Unit) [4].
The prognostic value of copeptin in HF patients has
been widely investigated and many studies suggest that el-
evated copeptin plasma concentration is a predictor of
mortality in HF [5]. What is less clear and more debatable
is the best moment for the performance of the dosage.
In a multicentric study published in 2014 by Vetrone
F. et al., 336 patients with dyspnea were enrolled in the
Emergency Departments (ED) of three University Hospi-
tals in Italy; the major aim of the study was to evaluate
the short term prognostic role of copeptin in patients di-
vided in HF and non-HF groups. Copeptin was mea-
sured at the admission and at the discharge from the
hospital and the follow-up time was 3 months. Copeptin
at admission was validated as a short term prognostic
factor; however, the original finding of this study, was
the prognostic role of copeptin measured at discharge;
similarly, a lower reduction or an increase in copeptin
concentration from admission to discharge was a strong
prognostic predictor of unfavorable outcome [6].
Although several differences do exist between these two
studies, we think that some comparisons can be per-
formed: first of all the median copeptin concentrations at
enrollment (T0) measured by Vetrone et al. were higher
with respect to those measured by Winther et al.
(42 pmol/L vs 22.2 pmol/L respectively in HF patients and
20 pmol/L vs less than 9 pmol/L in patients with non HF-
related dyspnea). These differences can be explained by
the different setting of the enrollment, since Winther et al.
set T0 within the first 24 h after the hospital admission
while Vetrone et al. set T0 in an earlier phase, in the ED,
before starting any treatment. Although copeptin is more
stable with respect to arginine-vasopressin (AVP), its
plasma concentration may vary after the first hours of
treatment according to hemodynamic stabilization and
drugs administration.
The second point of discussion is the importance of
copeptin concentration at discharge, a relatively stable
clinical phase during which a balance is obtained in most
patients; in our opinion discharge copeptin concentration
can be assumed as the “standard” of the patient and this
value should be considered for the prognostic stratifica-
tion. Looking at the receiver operating characteristic
(ROC) curves presented by Vetrone et al., obtained pool-
ing all the patients studied and considering as categorical
variable the presence or absence of events (death or re-
hospitalization) during the 3 months follow-up, the area
under the curve (AUC) was 0.63 considering T0 copeptin
concentration and 0.83 considering copeptin concentra-
tion at discharge from the hospital. In our opinion this is a
very important result, opening new perspectives for the
use of copeptin as prognostic marker in HF patients. It
should be, however, stressed that in the Italian cohort, the
follow-up was 3 months, significantly shorter than in
Winther’s study. Therefore, the prognostic value of copep-
tin at discharge deserves a more specific evaluation for
longer follow-up periods.
As emergency physicians we are used to divide the
clinical path of patients affected by acute conditions in
three stages: in the first one, the ED approach, the prior-
ities are to rule out life threatening conditions, to per-
form a differential diagnosis and to stabilize the patient.
This latter can be obtained in the ED, with a short stay
in the observation unit or may require hospitalization.
The next phases are the discharge from the hospital and
the follow-up. We think that more data about the time
course of copeptin plasma concentration in these clinical
phases of different diseases (first of all HF) could be use-
ful in order to contribute to identify high-risk patients
requiring hospitalization or a closer follow-up.
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